Investing in Deciphera Pharmaceuticals, Inc. (DCPH)  ➔  Intrinsic value

Prev. close$33.01 
ModelValueUpside
Chepakovich$7.79-76%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$33.01  
Valuation MethodValuePotential 
Chepakovich Model$7.79-76%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

5 May

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat => Zacks 11:54AM

Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2021 Earnings Call Transcript => Motley Fool 7:30AM

4 May

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates => Zacks 5:55PM

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results => Business Wire 4:22PM

Deciphera Pharmaceuticals, Inc. to Host Earnings Call => ACCESSWIRE 2:30PM

27 Apr

Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021 => Business Wire 7:00AM

20 Apr

When Will Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Turn A Profit? => Simply Wall St. 3:05AM

8 Apr

Is DCPH Stock A Buy or Sell? => Insider Monkey 2:01PM

31 Mar

China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) => GlobeNewswire 4:57AM

22 Mar

Deciphera Pharmaceuticals, Inc. (DCPH) Surges 8.8%: Is This an Indication of Further Gains? => Zacks 7:57AM

2 Mar

Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference => Business Wire 7:00AM

18 Feb

Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference => Business Wire 7:00AM

10 Feb

Broker Revenue Forecasts For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Are Surging Higher => Simply Wall St. 11:29PM

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss => Zacks 10:21AM

Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 => Benzinga 10:05AM

9 Feb

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Call Transcript => Motley Fool 10:00PM

Recap: Deciphera Pharmaceuticals Q4 Earnings => Benzinga 5:31PM

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates => Zacks 5:15PM

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results => Business Wire 4:01PM

Deciphera Pharmaceuticals, Inc. to Host Earnings Call => ACCESSWIRE 2:30PM

8 Feb

Baudax (BXRX) to Report Q4 Earnings: What's in the Cards? => Zacks 9:58AM

Investors Who Bought Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Three Years Ago Are Now Up 97% => Simply Wall St. 12:35AM

4 Feb

Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day => Business Wire 7:00AM

2 Feb

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021 => Business Wire 7:00AM

11 Jan

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones => Business Wire 7:00AM

5 Jan

Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference => Business Wire 7:23AM

20 Dec

DCPH Stock Forecast: Where Do Hedge Funds Stand? => Insider Monkey 10:04PM

18 Dec

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals => Zacks 12:14PM

1 Dec

Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment => Zacks 10:04AM

30 Nov

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor => Business Wire 7:00AM

24 Nov

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference => Business Wire 4:01PM

23 Nov

The Boston Globe Names Deciphera a Top Place to Work for 2020 => Business Wire 7:00AM

11 Nov

Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting => Business Wire 7:01AM

Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting => Business Wire 7:00AM

10 Nov

Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference => Business Wire 7:00AM

News Flash: Analysts Just Made A Sizeable Upgrade To Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasts => Simply Wall St. 5:29AM

9 Nov

Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3 => Zacks 10:18AM

6 Nov

Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2020 Earnings Call Transcript => Motley Fool 10:31PM

5 Nov

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results => Business Wire 4:01PM

Deciphera Pharmaceuticals, Inc. to Host Earnings Call => ACCESSWIRE 2:45PM

Company description

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.